These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 9247586

  • 1. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice.
    Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Büschenfelde KH, Strober W, Kollias G.
    Eur J Immunol; 1997 Jul; 27(7):1743-50. PubMed ID: 9247586
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
    Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP.
    Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
    [Abstract] [Full Text] [Related]

  • 4. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.
    Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, Cong Y, Black CA, Ridwan BW, McGhee JR.
    J Immunol; 1996 Sep 01; 157(5):2174-85. PubMed ID: 8757344
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of the cholinergic anti-inflammatory pathway on experimental colitis.
    Bai A, Guo Y, Lu N.
    Scand J Immunol; 2007 Nov 01; 66(5):538-45. PubMed ID: 17953529
    [Abstract] [Full Text] [Related]

  • 7. IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation.
    Mudter J, Yu J, Amoussina L, Weigmann B, Hoffman A, Rücknagel K, Galle PR, Neurath MF.
    Arch Immunol Ther Exp (Warsz); 2009 Nov 01; 57(5):369-76. PubMed ID: 19693649
    [Abstract] [Full Text] [Related]

  • 8. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
    Sun X, Somada S, Shibata K, Muta H, Yamada H, Yoshihara H, Honda K, Nakamura K, Takayanagi R, Tani K, Podack ER, Yoshikai Y.
    Gastroenterology; 2008 Feb 01; 134(2):447-58. PubMed ID: 18242212
    [Abstract] [Full Text] [Related]

  • 9. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
    Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M.
    Eur J Immunol; 1996 Apr 01; 26(4):934-8. PubMed ID: 8625991
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis.
    Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, Akiba H, Yagita H, Okumura K, Watanabe M.
    Am J Physiol Gastrointest Liver Physiol; 2003 Apr 01; 284(4):G595-603. PubMed ID: 12631559
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo.
    Holtmann MH, Douni E, Schütz M, Zeller G, Mudter J, Lehr HA, Gerspach J, Scheurich P, Galle PR, Kollias G, Neurath MF.
    Eur J Immunol; 2002 Nov 01; 32(11):3142-51. PubMed ID: 12555659
    [Abstract] [Full Text] [Related]

  • 12. Preventive effects of Schistosoma japonicum ova on trinitrobenzenesulfonic acid-induced colitis and bacterial translocation in mice.
    Zhao Y, Zhang S, Jiang L, Jiang J, Liu H.
    J Gastroenterol Hepatol; 2009 Nov 01; 24(11):1775-80. PubMed ID: 20136961
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis.
    Yang X, Meng S, Jiang H, Chen T, Wu W.
    Scand J Gastroenterol; 2010 Oct 01; 45(10):1168-77. PubMed ID: 20469967
    [Abstract] [Full Text] [Related]

  • 16. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice.
    Katchar K, Kelly CP, Keates S, O'brien MJ, Keates AC.
    Am J Physiol Gastrointest Liver Physiol; 2007 May 01; 292(5):G1263-71. PubMed ID: 17272517
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.
    Zuo L, Huang Z, Dong L, Xu L, Zhu Y, Zeng K, Zhang C, Chen J, Zhang J.
    Gut; 2010 Apr 01; 59(4):470-9. PubMed ID: 19951904
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model.
    Pender SL, Chance V, Whiting CV, Buckley M, Edwards M, Pettipher R, MacDonald TT.
    Gut; 2005 Aug 01; 54(8):1114-20. PubMed ID: 16009684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.